EP1307204A4 - Protease inhibitors - Google Patents

Protease inhibitors

Info

Publication number
EP1307204A4
EP1307204A4 EP01946344A EP01946344A EP1307204A4 EP 1307204 A4 EP1307204 A4 EP 1307204A4 EP 01946344 A EP01946344 A EP 01946344A EP 01946344 A EP01946344 A EP 01946344A EP 1307204 A4 EP1307204 A4 EP 1307204A4
Authority
EP
European Patent Office
Prior art keywords
protease inhibitors
protease
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01946344A
Other languages
German (de)
French (fr)
Other versions
EP1307204A1 (en
Inventor
Robert W Marquis Jr
Yu Ru
Daniel F Veber
Maxwell D Cummings
Scott K Thompson
Dennis Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1307204A1 publication Critical patent/EP1307204A1/en
Publication of EP1307204A4 publication Critical patent/EP1307204A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP01946344A 2000-06-14 2001-06-14 Protease inhibitors Withdrawn EP1307204A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59384500A 2000-06-14 2000-06-14
US593845 2000-06-14
PCT/US2001/019062 WO2001095911A1 (en) 2000-06-14 2001-06-14 Protease inhibitors

Publications (2)

Publication Number Publication Date
EP1307204A1 EP1307204A1 (en) 2003-05-07
EP1307204A4 true EP1307204A4 (en) 2004-06-02

Family

ID=24376433

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01946344A Withdrawn EP1307204A4 (en) 2000-06-14 2001-06-14 Protease inhibitors

Country Status (25)

Country Link
EP (1) EP1307204A4 (en)
JP (1) JP2004503502A (en)
KR (1) KR20030008220A (en)
CN (1) CN1444481A (en)
AP (1) AP2002002671A0 (en)
AR (1) AR032622A1 (en)
AU (1) AU2001268407A1 (en)
BG (1) BG107327A (en)
BR (1) BR0111693A (en)
CA (1) CA2412353A1 (en)
CZ (1) CZ20024086A3 (en)
EA (1) EA200300018A1 (en)
EC (1) ECSP024388A (en)
HU (1) HUP0301231A2 (en)
IL (1) IL153421A0 (en)
MA (1) MA25758A1 (en)
MX (1) MXPA02012442A (en)
NO (1) NO20025786L (en)
NZ (1) NZ522965A (en)
OA (1) OA12288A (en)
PE (1) PE20011374A1 (en)
PL (1) PL360508A1 (en)
SK (1) SK17592002A3 (en)
WO (1) WO2001095911A1 (en)
ZA (1) ZA200209808B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034158A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513927A (en) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
IL155997A0 (en) * 2000-11-22 2003-12-23 Smithkline Beecham Corp Protease inhibitors
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
IL156827A0 (en) 2001-02-20 2004-02-08 Chugai Pharmaceutical Co Ltd Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
WO2002092563A2 (en) * 2001-05-17 2002-11-21 Smithkline Beecham Corporation Protease inhibitors
JP4648317B2 (en) 2003-08-01 2011-03-09 中外製薬株式会社 Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors
ATE487475T1 (en) 2003-08-01 2010-11-15 Chugai Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS AS USEFUL MALONYL-COA DECARBOXYLASE INHIBITORS
ES2314491T3 (en) 2003-08-01 2009-03-16 Chugai Seiyaku Kabushiki Kaisha AZOL COMPOUNDS BASED ON CYANOGUANIDINE USEFUL AS INHIBITORS OF MANONYL-COA DESCARABOXYLASE.
JP5587790B2 (en) 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド Compound
CN103275070A (en) * 2013-05-10 2013-09-04 郑彪 Tetracyclic compound for adjusting proliferation of mononuclear cells and application of tetracyclic compound
US9427441B2 (en) 2014-02-19 2016-08-30 Indiana University Research And Technology Corporation Targeting primary cilia to treat glaucoma

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005336A1 (en) * 1996-08-08 1998-02-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
WO2001034565A2 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034158A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2002017924A1 (en) * 2000-09-01 2002-03-07 Smithkline Beecham Corporation Method of treatment
WO2002092563A2 (en) * 2001-05-17 2002-11-21 Smithkline Beecham Corporation Protease inhibitors
WO2003053331A2 (en) * 2000-11-22 2003-07-03 Smithkline Beecham Corporation Protease inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100630986B1 (en) * 1998-12-23 2006-10-09 스미스클라인 비참 코포레이션 Protease Inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005336A1 (en) * 1996-08-08 1998-02-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
WO2001034565A2 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034158A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2002017924A1 (en) * 2000-09-01 2002-03-07 Smithkline Beecham Corporation Method of treatment
WO2003053331A2 (en) * 2000-11-22 2003-07-03 Smithkline Beecham Corporation Protease inhibitors
WO2002092563A2 (en) * 2001-05-17 2002-11-21 Smithkline Beecham Corporation Protease inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO0195911A1 *
VEBER, DANIEL F. ET AL: "The role of conformational constraint in improved oral bioavailability of cathepsin K inhibitors", PEPTIDES 2000, PROCEEDINGS OF THE EUROPEAN PEPTIDE SYMPOSIUM, 26TH, MONTPELLIER, FRANCE, SEPT. 10-15, 2000 ( 2001 ), MEETING DATE 2000, 113-114. EDITOR(S): MARTINEZ, JEAN;FEHRENTZ, JEAN-ALAIN. PUBLISHER: EDITIONS EDK, PARIS, FR., XP009028910 *

Also Published As

Publication number Publication date
HUP0301231A2 (en) 2003-08-28
BG107327A (en) 2003-07-31
WO2001095911A1 (en) 2001-12-20
CZ20024086A3 (en) 2003-05-14
MXPA02012442A (en) 2003-04-25
BR0111693A (en) 2004-04-06
EA200300018A1 (en) 2003-06-26
JP2004503502A (en) 2004-02-05
AU2001268407A1 (en) 2001-12-24
PL360508A1 (en) 2004-09-06
AP2002002671A0 (en) 2002-12-31
NO20025786D0 (en) 2002-12-02
NZ522965A (en) 2004-06-25
AR032622A1 (en) 2003-11-19
ZA200209808B (en) 2004-07-09
KR20030008220A (en) 2003-01-24
CA2412353A1 (en) 2001-12-20
SK17592002A3 (en) 2003-05-02
NO20025786L (en) 2003-02-12
ECSP024388A (en) 2003-02-06
IL153421A0 (en) 2003-07-06
EP1307204A1 (en) 2003-05-07
PE20011374A1 (en) 2002-04-07
CN1444481A (en) 2003-09-24
MA25758A1 (en) 2003-04-01
OA12288A (en) 2003-12-12

Similar Documents

Publication Publication Date Title
AP2002002593A0 (en) Protease inhibitors
GB0125445D0 (en) Protease Inhibitors
IL215891A0 (en) Peptidomimetic protease inhibitors
IL153421A0 (en) Protease inhibitors
EP1235577A4 (en) Protease inhibitors
EP1232155A4 (en) Protease inhibitors
IL151087A0 (en) Protease inhibitors
EP1229914A4 (en) Protease inhibitors
EP1229912A4 (en) Protease inhibitors
EP1229915A4 (en) Protease inhibitors
EP1231921A4 (en) Protease inhibitors
EP1229911A4 (en) Protease inhibitors
EP1233771A4 (en) Protease inhibitors
HK1043534A1 (en) Protease inhibitors
EP1351930A4 (en) Protease inhibitors
EP1173429A4 (en) Protease inhibitors
EP1401453A4 (en) Protease inhibitors
EP1231923A4 (en) Protease inhibitors
HUP0301964A2 (en) Protease inhibitors
IL155961A0 (en) Cysteine protease inhibitors
EP1232154A4 (en) Protease inhibitors
EP1231922A4 (en) Protease inhibitors
AU6407701A (en) Serine protease inhibitors
GB0009123D0 (en) Protease inhibitor
ZA200207478B (en) Protease inhibitors.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030114

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040420

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 19/00 B

Ipc: 7A 61P 35/04 B

Ipc: 7A 61P 33/00 B

Ipc: 7A 61P 31/00 B

Ipc: 7A 61P 29/00 B

Ipc: 7C 07D 417/14 B

Ipc: 7C 07D 471/04 B

Ipc: 7C 07D 409/14 B

Ipc: 7C 07D 403/12 B

Ipc: 7C 07D 401/14 B

Ipc: 7C 07D 401/10 B

Ipc: 7C 07D 405/14 B

Ipc: 7C 07D 401/12 B

Ipc: 7C 07D 409/12 B

Ipc: 7C 07D 405/12 B

Ipc: 7A 61K 31/55 A

17Q First examination report despatched

Effective date: 20060810

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090630

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1057327

Country of ref document: HK